IVERIC bio, Inc.(ISEE) Stock Research - Grey Stern Research

IVERIC bio, Inc. (ISEE) Stock Analysis

$39.95 (0.38%)

ISEE Financial Performance


Use the table below to view IVERIC bio, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2023

Metric Value Ranking among Peers
Price $39.95 -
52 Week Low $9.39 -
52 Week High $39.99 -
Market Cap $5.5 Billion 7/18
Gross Margin 0% 12/18
Profit Margin 0% 4/18
EBITDA margin -100% 5/18
Q1 - 2023 Revenue $0 12/18
Q1 - 2023 Earnings -$70.6 Million 15/18
Q1 - 2023 Free Cash Flow -$50.8 Million 12/18
Trailing 4 Quarters Revenue $0 14/18
Trailing 4 Quarters Earnings -$213.5 Million 14/18
Quarterly Earnings Growth -104% 18/18
Annual Earnings Growth -60% 16/18
Quarterly Revenue Growth 0% 8/18
Annual Revenue Growth 0% 10/18
Cash On Hand $467.6 Million 4/18
Short Term Debt $774,000 11/18
Long Term Debt $97.0 Million 6/18

IVERIC bio, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare IVERIC bio, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/18
PS -1.00 14/18
PB 11.55 5/18
PC 11.79 9/18
Liabilities to Equity 0.29 7/18
ROA -0.35 12/18
ROE -0.45 10/18
Current Ratio 4.50 12/18
Quick Ratio 4.40 10/18
Long Term Debt to Equity 0.20 5/18
Debt to Equity 0.20 5/18
Burn Rate 6.26 6/18
Cash to Cap 0.08 10/18
CCR 0.72 10/18
EV to EBITDA -1.00 2/18
EV to Revenue -1.00 14/18

Company Details

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

CEO: Mr. Glenn Sblendorio

Website: https://ivericbio.com

Address: 1 Penn Plz Fl 35 New York City, NEW YORK

Exchange: NASDAQ Global Select

Industry: Biotechnology

IVERIC bio, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to IVERIC bio, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $7.4 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $5.3 Billion
Blueprint Medicines Corporation BPMC $5.5 Billion
Apellis Pharmaceuticals, Inc. APLS $4.4 Billion
Krystal Biotech, Inc. KRYS $5.8 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Stoke Therapeutics, Inc. STOK $761.8 Million
Immunovant, Inc. IMVT $4.3 Billion
89bio, Inc. ETNB $869.5 Million
Pliant Therapeutics, Inc. PLRX $729.6 Million
Prometheus Biosciences, Inc. RXDX $9.6 Billion
Terns Pharmaceuticals, Inc. TERN $736.9 Million
Day One Biopharmaceuticals, Inc. DAWN $1.2 Billion
Roivant Sciences Ltd. ROIV $8.8 Billion
Arcellx, Inc. ACLX $4.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ISEE Income Statements
Quarter Year Revenue Earnings
Q1 2023 $ 0 -$70.6 Million
Q4 2022 $ 0 -$51.3 Million
Q3 2022 $ 0 -$42.4 Million
Q2 2022 $ 0 -$49.3 Million
Q1 2022 $ 0 -$34.5 Million
Q4 2021 $ 0 -$33.0 Million
Q3 2021 $ 0 -$24.6 Million
Q2 2021 $ 0 -$30.1 Million

View All

ISEE Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2023 $467.6 Million $613.4 Million $97.8 Million $477.0 Million
Q4 2022 $476.3 Million $666.8 Million $97.8 Million $534.7 Million
Q3 2022 $153.1 Million $331.8 Million $1.6 Million $259.5 Million
Q2 2022 $141.1 Million $319.8 Million $2.1 Million $292.9 Million
Q1 2022 $191.9 Million $352.7 Million $1.3 Million $333.2 Million
Q4 2021 $261.4 Million $389.4 Million $1.6 Million $360.5 Million
Q3 2021 $179.9 Million $247.8 Million $1.8 Million $226.5 Million
Q2 2021 $50.4 Million $165.7 Million $2.0 Million $139.6 Million

View All

ISEE Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2023 -$50.8 Million -$233,000 -$8.7 Million
Q4 2022 -$49.5 Million -$296,000 $323.2 Million
Q3 2022 -$41.3 Million -$229,000 $12.0 Million
Q2 2022 -$36.0 Million -$95,000 -$50.8 Million
Q1 2022 -$37.6 Million -$116,000 -$69.6 Million
Q4 2021 -$22.8 Million -$361,000 $81.6 Million
Q3 2021 -$26.2 Million $0 $129.5 Million
Q2 2021 -$20.5 Million $0 $21.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions